Statins for acute coronary syndrome

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Vale, Noah ^a   Nordmann, Alain J ^b   Schwartz, Gregory G ^c   de Lemos, James ^d   Colivicchi, Furio ^e   den Hartog, Frank ^f   Ostadal, Petr ^g   Macin, Stella M ^h   Liem, Anho H ⁱ   Mills, Edward J ^j   Bhatnagar, Neera ^k   Bucher, Heiner C ^b   Briel, Matthias ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e SAN FILIPPO NERI HOSPITAL   (Italy)

^f GELDERSE VALLEI HOSPITAL   (Netherlands)

^g NA HOMOLCE HOSPITAL   (Czech Republic)

^h Instituto de Cardiología de Corrientes Juana F Cabral   (Argentina)

ⁱ Faculty of Health Sciences ^*  (Netherlands)

^j UNIVERSITY OF OTTAWA   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADULT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MORTALITY; MUSCLE DISEASE; MYOPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DRUG ADMINISTRATION; HEART FAILURE; META ANALYSIS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; UTILIZATION;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84921874378     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006870.pub3     Document Type: Review

References (137)

1. Colivicchi F, Guido V, Tubaro M, Ammirati F, Montefoschi N, Varveri A, et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. American Journal of Cardiology 2002;90(8):872-4.
2. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16.
3. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004;110(9):1061-8.
4. Ostadal P, Alan D, Hajek P, Vejvoda J, Mates M, Blasko P, et al. Fluvastatin in the therapy of acute coronary syndrome: rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial). Current Controlled Trials in Cardiovascular Medicine 2005;6(1):4. [: ISRCTN 81331696]
5. Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, et al. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials 2010;11(1):61.
6. Liem AH, van Boven AJ, Veeger NJGM, Withagen AJ, Robles de Medina RM, Tijssen JGP, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. European Heart Journal 2002;23(24):1931-7.
7. Kesteloot H, Claeys G, Blanckaert N, Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiologica 1997;52(2):107-16.
8. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study). American Journal of Cardiology 2000;86(12):1293-8.
9. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215.
10. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. American Heart Journal 2005;149(3):451-7.
11. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711.
12. Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID study. Circulation 2008;72(1):17.
13. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. American Heart Journal 2004;148(1):91.
14. den Hartog FR, van Kalmthout PM, van Loenhout TT, Schaafsma HJ, Rila H, Verheugt FW. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial. International Journal of Clinical Practice 2001;55(5):300.
15. LaBlanche JM, Wright RS, Jukema JW, Charbonneau F, Creplet J, Eldar M, et al. Reductions in early recurrent coronary ischemia from early administration of statin therapy upon admission for myocardial infarction: results of the PRINCESS trial. Circulation 2004;110(17):2339.
16. Wright RS. PRINCESS: Prevention of ischaemic events by early treatment of cerivastatin after acute myocardial infarction. Hotline session III., European Society of Cardiology. 2004.
17. Kayikcioglu M, Can L, Evrengul H, Payzin S, Kultursay H. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. International Journal of Cardiology 2003;90(1):63-72.
18. Kayikcioglu M, Turkoglu C, Kltrsay H, Evrengul H, Can L. The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation 1999;100(SUPPL.1):I-303. Abstract 1586.
19. Kayikcioglu M, Turkoglu C, Kultursay H, Harum H, Can L. Combined use of pravastatin and thrombolytic agents in acute myocardial infarction. Pravastatin turkish trial (PTT). Circulation 1999;100(SUPPL.1):1-303.
20. Kayikçioglu M, Can L, Kültürsay H, Payzin S, Turkoglu C. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiologica 2002;57(4):295.
21. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99(25):3227.
22. Ren HZ, Ma LL, Wang LX. Effect of simvastatin on plasma interleukin-6 in patients with unstable angina. Clinical and Investigative Medicine. Médecine Clinique et Experimentale 2009;32(4):E280.
23. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. American Journal of Cardiology 2006;97(8):1165-71.
24. Shal'nev VI. The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome. Klinicheskaia Meditsina 2007;85(11):46-50.
25. Akasaka T, Komukai K, Ishibashi K, Tanimoto T, Matsuo Y, Ino Y, et al. Effect of intensive vs. moderate lipid-lowering therapy with atorvastatin on the stabilization of atherosclerosis in acute coronary syndromes: serial optical coherence tomography analysis. European Heart Journal 2012;33:355.
26. Barderas MG, Tunón J, Dardé VM, De la Cuesta F, Jiménez-Nácher JJ, Tarin N, et al. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. Proteomics 2009;9(7):1982-93.
27. Bermejo J, Segovia J, Alfonso F. Summary of the Clinical Studies Reported in the Scientific Sessions in the American Heart Association 2005 (Dallas, Texas, USA, 13-16 November 2005). Revista Espanola de Cardiologia (Internet) 2006;59(2):143-53.
28. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004;350(15):1495-504.
29. Chi H, Wang S, Chen J, Zhang J. Long-term effects of simvastatin on protection against atrial fibrillation in patients with acute myocardial infarction. Journal of Geriatric Cardiology 2007;4(3):144.
30. Chiodini BD, Franzosi MG, Barlera S, Signorini S, Lewis CM, D'Orazio A, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. European Heart Journal 2007;28(16):1977-83.
31. Chyrchel M, Dudek D, Rzeszutko L, Dziewierz A, Chyrchel B, Rakowski T, et al. Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. Cardiovascular Revascularization Medicine 2011;12:2-9.
32. Colivicchi F, Tubaro M, Mocini D, Genovesi EA, Strano S, Melina G, et al. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Current Medical Research and Opinion 2010;26(6):1277-84.
33. Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, et al. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Current Medical Research & Opinion 2010;26:1277-84.
34. Colivicchi F, Colaiaco C, Golia E, Tubaro M, Aiello A, Aspromonte N, et al. Full-dose atorvastatin reduces hospitalizations for heart failure after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Giornale Italiano di Cardiologia 2011;1:15S.
35. Correia LC, Sposito AC, Passos LC, Lima JC, Braga JC, Rocha MS, et al. Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. American Journal of Cardiology 2002;90(2):162-4.
36. de Winter RJ, Windhausen F, Cornel JH, Dunselman PHJM, Janus CL, Bendermacher PEF, et al. Early invasive versus selectively invasive management for acute coronary syndromes. New England Journal of Medicine 2005;353(11):1095.
37. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis 2010;210:497-502.
38. Wojakowski W, Maslankiewicz K, Ochala A, Pyrlik A, Ciosek J, Wieja P, et al. Early treatment with simvastatin in myocardial infarction to reduce the levels of multiple inflammatory markers in 6-month follow-up. FLAME randomized clinical trial. Circulation 2006;114:II_650-1.
39. Ge J, Kim YJ, Jang YS, Zhu J, Marschner IC, Lam W. Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes. Journal of Cardiology 2010;55:303-8.
40. Gómez-Doblas JJ, Jimenez-Navarro MF, Garcia-Pinilla JM, Rodriguez-Bailon I, Robledo J, Cabrera F, et al. Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium) [Influencia del tratamiento temprano con estatinas en la función endotelial tras el infarto de miocardio en pacientes con valores normales de colesterol. Estudio VAATOPE]. Medicina Clinica 2006;126(9):325-8.
41. Gómez-Hernández A, Sánchez-Galán E, Ortego M, Martin-Ventura JL, Blanco-Colio LM, Tarin-Vicente N, et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. American Journal of Cardiology 2008;102:12-8.
42. Guazzi M, Tumminello G, Reina G, Vicenzi M, Guazzi MD. Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. European Journal of Clinical Investigation 2007;37(6):454-62.
43. Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention & Rehabilitation 2009;16:712-21.
44. He XZ, Zhou SH, Wan XH, Wang HY, Zhong QH, Xue JF. The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome. Clinical Cardiology 2011;34:59-63.
45. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). Journal of the American College of Cardiology 2009;54(4):293-302.
46. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). Journal of the American College of Cardiology 2009;54(4):293-302.
47. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circulation Journal 2010;74:1165-74.
48. Kanadaşi M, Çayli M, Demirtaş M, Inal T, Demir M, Koç M, et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart and Vessels 2006;21(5):291-7.
49. Kashima Y, Izawa A, Aizawa K, Koshikawa M, Kasai H, Tomita T, et al. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Journal of Cardiology 2009;54(1):76-9.
50. Kuznetsova MA, Vaulin NA, Masenko VP, Gratsianskii NA. Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation. Kardiologiia 2010;50:21-5.
51. Lablanche JM, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design. Archives of Cardiovascular Diseases 2008;101(6):399-406.
52. Wojakowski W, Michalowska A, Majka M, Maslankiewicz K, Wyderka R, Krol M, et al. Early treatment with fluvastatin enhances the mobilization of CD34+, CD117+, CXCR4+, C-met+ stem cells into peripheral blood in patients with acute myocardial infarction: LAVA trial. Journal of the American College of Cardiology 2005;45(SUPPL.A, February):A197-8.
53. Lemos PA, de Feyter PJ, Serruys PW, Saia F, Arampatzis CA, Disco C, et al. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. International Journal of Cardiology 2005;98(3):479-86.
54. Leone AM, Rutella S, Giannico MB, Perfetti M, Zaccone V, Brugaletta S, et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology 2008;130:457-62.
55. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clinical Chemistry 2005;51(9):1735.
56. Li JJ, Li YS, Fang CH, Hui RT, Yang YJ, Cheng JL, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. BMJ 2006;92(4):529.
57. Lim SY, Bae EH, Choi JS, Kim CS, Park JW, Ma SK, et al. Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction. American Journal of Cardiology 2012;109:1425-30.
58. Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. European Heart Journal 2006;27(24):2945.
59. Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. European Heart Journal 2006;27:2945-55.
60. Link A, Selejan S, Hewera L, Walter F, Nickenig G, Bohm M. Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes. Clinical Research in Cardiology 2011;100:147-58.
61. Liu P, Jiang J, Li J, Hong T, Zhang Y, Yu R, et al. Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design. Catheterization & Cardiovascular Interventions 2012;79:967-71.
62. Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circulation Journal 2006;70:1624-8.
63. Monteiro CMC, Oliveira L, Izar MCO, Santos AO, Povoa RMS, Fischer SM, et al. Early effects of lipid lowering treatment in subjects with metabolic syndrome and acute coronary syndromes. International Journal of Atherosclerosis 2008;3:93-9.
64. Nakamura T, Obata J, Kitta Y, Takano H, Kobayashi T, Fujioka D, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. Journal of Cardiovascular Pharmacology 2008;51(4):365.
65. Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, Yamazaki T, et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. International Journal of Cardiology 2005;105(1):67-73.
66. Ordulu E, Erdogan O. Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. International Journal of Cardiology 2008;128(2):282-4.
67. Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Molecular and Cellular Biochemistry 2003;246(1-2):45-50.
68. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. Journal of the American College of Cardiology 2007;49(12):1272-8.
69. Min Z, Zhao M, Jia SQ. Pravastatin early use in acute coronary evaluation (PEACE) trial. American Journal of Cardiology 2005;95(SUPPL.8, April):74A.
70. Pedersen TR, Jahnsen KE, Vatn S, Semb AG, Kontny F, Zalmai A, et al. Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study. Clinical Therapeutics 2000;22(8):949-60.
71. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294(19):2437.
72. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. Journal of the American College of Cardiology 2008;51(15):1440-5.
73. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). American Journal of Cardiology 2012;109:1239-46.
74. Post S, Post MC, Van Den Branden BJ, Eefting FD, Goumans MJ, Stella PR, et al. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheterization and Cardiovascular Interventions 2012;80:756-65.
75. Sakata Y, Sato H, Kinjo K, Fujii K, Kodama K, Tanouchi J, et al. Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction. Heart Drug 2005;5(4):193-6.
76. Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Experimental and Clinical Cardiology 2007;12(2):91-6.
77. Stefanadi E, Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Vavuranakis E, et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. International Journal of Cardiology 2009;133(2):266-8.
78. Suh SY, Rha SW, Ahn TH, Shin EK, Choi CU, Oh DJ, et al. Long-term safety and efficacy of pitavastatin in patients with acute myocardial infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS]). American Journal of Cardiology 2011;108:1530-5.
79. Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. Journal of Cardiology 2009;53(1):58-64.
80. Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Kotsopoulou M, Tsioufis C, et al. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. International Journal of Cardiology 2006;109:48-52.
81. Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Kotsopoulou M, Tsioufis C, et al. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. International Journal of Cardiology 2006;109(1):48-52.
82. Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. International Journal of Cardiology 2006;106(3):333-7.
83. Xin-wei JIA, Xiang-hua FU, Jing Z, Xin-shun GU, Wei-ze FAN, Wei-li WU, et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chinese Medical Journal 2009;122(6):659-64.
84. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. International Journal of Cardiology 2009;137(3):246-51.
85. Zhang X, Wang H, Liu S, Gong P, Lin J, Lu J, et al. Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions. Journal of Cardiovascular Pharmacology and Therapeutics 2013;18:119-25.
86. Zhao Z, Geng J, Ge ZM, Wang W, Zhang Y, Kang WQ. Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Clinical and Experimental Pharmacology & Physiology 2009;36(5-6):554-8.
87. Zheng XY, Liu L, Yang DG. Early effect of atorvastatin, alone and in combination with probucol, on endothelial dysfunction in patients with acute coronary syndrome. Atherosclerosis Supplements 2009;Conference.
88. Zheng XY, Liu L, Zhao SP. Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2009;37:900-3.
89. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
90. American Heart Association. Heart disease and stroke statistics - 2007 update. Available at www.americanheart.org/statistics 2006 (accessed August 2007).
91. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8.
92. Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technology Assessment 2009;13(34):1-118.
93. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69.
94. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, LincoffAM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357(9262):1063-8.
95. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81.
96. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. American Journal of Medicine 2004;117(8):596-606.
97. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004;350(15):1495-504.
98. Deeks J, Bradburn M, Localio R, Berlin J. Much ado about nothing: statistical methods for meta-analysis with rare events. 6th Cochrane Colloquium, Baltimore, MD, USA. 1998.
99. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
100. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91.
101. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. American Journal of Cardiology 2005;96(5):611-6. [MEDLINE: 680]
102. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003;289(19):2554-9.
103. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Annals of Internal Medicine 1996;124(11):999-1005.
104. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [MEDLINE: 533]
105. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 411]
106. The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22. [MEDLINE: 11]
107. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome. A meta-analysis of randomized controlled trials. Archives of Internal Medicine 2006;166:1814-21.
108. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462-7.
109. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings 2009;84(10):917-38.
110. Lachin JM. Sample size, power, and efficiency. In: Lachin JM editor(s). Biostatistical Methods. 1st Edition. New York: John Wiley & Sons, 2000:61-86.
111. Laupacis A, Mamdani M. Observational studies of treatment effectiveness: some cautions. Annals of Internal Medicine 2004;140(11):923-4.
112. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
113. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998;339(19):1349-57.
114. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite end points in clinical trials. BMJ 2005;330(7491):594-6.
115. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence?. Journal of the American College of Cardiology 2009;54(15):1425-33.
116. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287(23):3087-95. [MEDLINE: 349]
117. Nordmann A, Blattmann L, Gallino A, Khetari R, Martina B, Muller P, et al. Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control. European Journal of Internal Medicine 2000;11(6):309-16.
118. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. New England Journal of Medicine 1998;338(21):1516-20.
119. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98(9):839-44. [MEDLINE: 34]
120. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279(20):1643-50. [MEDLINE: 21]
121. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215-22.
122. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995;333(20):1301-7.
123. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. American Heart Journal 2005;149(3):444-50.
124. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Annals of Internal Medicine 2004;140(11):857-66.
125. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arteriosclerosis, Thrombosis & Vascular Biology 2002;22(10):1524-34.
126. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine 2002;346(7):539-40.
127. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285(4):430-6.
128. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323(7304):101-5.
129. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 7 [Epub ahead of print]. [DOI: 10.1016/j.jacc.2013.11.002]
130. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Archives of Internal Medicine 2005;165(7):725-30.
131. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. European Heart Journal 2007;28(20):2525-38.
132. Walter DH. Insights into early and rapid effects of statin therapy after coronary interventions. Current Pharmaceutical Design 2004;10(4):369-73.
133. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. European Heart Journal 1998;19(10):1434-503.
134. Briel M, Schwartz GG, Thompson PL, DeLemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes. A meta-analysis of randomized controlled trials. JAMA 2006;295:2046-56.
135. Briel M, Schwartz GG, Bucher HC, Nordmann AJ. 5012 Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal 2006;27(SUPPL.1):856.
136. Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, et al. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14, 000 patients. International Journal of Cardiology 2011 Feb 3 [Epub ahead of print].
137. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, et al. Statins for acute coronary syndrome. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD006870.pub2]